Germany vs Nepal: The number of people with susceptibility test result for rifampicin
Germany
83.72
in 2021
Nepal
81.26
in 2021
Germany rank
89th
Nepal rank
92nd
The number of people with susceptibility test result for rifampicin over time
- Germany
- Nepal
How they compare
Germany currently reports 83.72 against 81.26 in Nepal, a difference of 2.46.
Across all 5 years both countries report, Germany has been ahead every year.
Germany ranks 89th and Nepal ranks 92nd of 146 countries.
Germany has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Germany | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 87.11 | 43.61 | 43.51 | Germany |
| 2020s | 84.9 | 70.59 | 14.31 | Germany |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Germany or Nepal?
- Germany, at 83.72 against 81.26 in Nepal as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Germany and Nepal?
- 2.46, with Germany ahead.
- How many years of comparable data are there for Germany and Nepal?
- 5 years are reported by both, from 2017 to 2021.
- How do Germany and Nepal rank globally for the number of people with susceptibility test result for rifampicin?
- Germany ranks 89th and Nepal ranks 92nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.